ClinicalTrials.gg
CompletedNCT04005807Updated Jun 18, 2021

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

A Phase 1 interventional study of BPN-14967 and Placebo in Healthy Volunteers, sponsored by Belite Bio, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-18.

Sponsored by Belite Bio, Inc · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is single center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of BPN-14967 in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Belite Bio, Inc is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is male or female (not of ), 18 to 65 years of age, inclusive, at screening.
  • The subject voluntarily consents to participate in this study and
  • provides written before the start of any study-specific procedures.
  • The subject is willing and able to remain in the study unit for the entire duration of the confinement period and return for outpatient visits.
  • Female subjects must be of non-childbearing potential (defined as surgically sterile [i.e., had a bilateral tubal ligation, hysterectomy, or
  • bilateral oophorectomy at least 6 months before the dose of study drug] or for at least 1 year before study drug administration confirmed by FSH test at screening).
  • Male subjects must be surgically sterile (i.e., vasectomy) for at least 3 months before screening; or agree to use a condom with spermicide when sexually active with a female partner. Male subjects must also agree to refrain from sperm donation for 90 days after study drug administration.
  • The subject has a (BMI) of 18 to 30 kg/m2, inclusive, at screening and weighs 50 to 100 kg (110-220 pounds), inclusive, at screening and Check-in.
  • The subject is considered to be in stable health by the investigator

Exclusion criteria

Exclusion Criteria

  • Any significant acute or chronic medical illness including history or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease
  • Any recent viral or bacterial infection.
  • Participated in any clinical study in last 6 weeks.
  • History of significant drug allergy
  • History of significant vision, ocular or retinal disorder.
  • Recent surgery, blood transfusion, drug or alcohol abuse and use of tobacco or nicotine containing products in past month.
  • Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECGs, or clinical laboratory determinations

Other protocol-defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1 (fasted condition)

    10 mg BPN-14967 or placebo

    Drug: BPN-14967 · Drug: Placebo

  • Experimental
    Cohort 2 (fasted condition)

    25 mg BPN-14967 or placebo

    Drug: BPN-14967 · Drug: Placebo

  • Experimental
    Cohort 3 (fasted condition)

    50 mg BPN-14967 or placebo

    Drug: BPN-14967 · Drug: Placebo

  • Experimental
    Cohort 4 (fed condition)

    10 mg BPN-14967 or placebo

    Drug: BPN-14967 · Drug: Placebo

  • Experimental
    Cohort 5 (high-fat fed condition)

    10 mg BPN-14967 or placebo

    Drug: BPN-14967 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve from time 0 to the last timepoint with quantifiable concentration [AUC(0-t)]

    Time frame: Up to Day 8

  2. Area under the plasma concentration versus time curve from time 0 extrapolated to infinity [AUC(0-inf)]

    Time frame: Up to Day 8

  3. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 8

  4. Time to maximum observed plasma concentration (Tmax)

    Time frame: Up to Day 8

  5. Terminal elimination rate constant

    Time frame: Up to Day 8

  6. Terminal phase half-life (t1/2)

    Time frame: Up to Day 8

  7. Apparent total body clearance (CL/F)

    Time frame: Up to Day 8

  8. Apparent volume of distribution (Vz/F)

    Time frame: Up to Day 8

  9. Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to discontinuation

    Time frame: Up to Day 10

  10. Number of participants with Clinical Laboratory Results Abnormalities

    Time frame: Up to Day 10

  11. Number of participants with Vital Sign Abnormalities

    Time frame: Up to Day 10

  12. Number of participants with Physical Examination Abnormalities

    Time frame: Up to Day 10

  13. Number of participants with 12-lead Electrocardiogram (ECG) Abnormalities

    Time frame: Up to Day 10

  14. Number of participants with changes in visual acuity

    Time frame: Baseline and Day 10

  15. Number of participants with Ocular Examination Abnormalities

    Time frame: Up to Day 10

  16. Number of participants with changes in color vision

    Time frame: Baseline and Day 10

07

Study locations

1 site
  • PPD Phase I Clinic
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No — After completion of the study, data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be responsible for these activities and will work with the investigators to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and any other related issues. The sponsor has final approval authority of all such issues. Data are the property of the sponsor and cannot be published without their prior authorization, but data and any publication thereof will not be unduly withheld.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Dec 2019, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2019
First posted
Jul 2, 2019
StartActual
Jul 19, 2019
Primary completionActual
Dec 20, 2019
CompletionActual
Dec 20, 2019
Last update
Jun 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04005807
Lead sponsor
Belite Bio, Inc
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Jul 19, 2019
Primary completion
Dec 20, 2019
Completion
Dec 20, 2019
Last update
Jun 18, 2021

Study contacts

Konstantin Petrukhin, PhD
study director · Professor of Ophthalmic Science, Department of Ophthalmology, Columbia University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinlarebant

Start the discussion